Market capitalization | $2.71b |
Enterprise Value | $2.27b |
P/E (TTM) P/E ratio | 91.48 |
EV/FCF (TTM) EV/FCF | 28.15 |
EV/Sales (TTM) EV/Sales | 2.54 |
P/S ratio (TTM) P/S ratio | 3.04 |
P/B ratio (TTM) P/B ratio | 5.24 |
Revenue growth (TTM) Revenue growth | 61.65% |
Revenue (TTM) Revenue | $890.53m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:
19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:
Dec '23 | |
Current assets | 616 616 |
Fixed assets | 133 133 |
Total Assets | 749 749 |
Dec '23 | |
Equity | 432 432 |
Debt capital | 317 317 |
Total Capital | 749 749 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Stephen Davis |
Employees | 598 |
Founded | 1993 |
Website | www.acadia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.